Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: Results of the first prospective randomized phase II trial;Neoadjuvante Radiochemotherapie mit Gemcitabin/Cisplatin gefolgt von Resektion versus primärer Resektion bei resektablem Pankreaskopfkarzinom: Ergebnisse der ersten prospektiven randomisierten Phase-II-Studie

Strahlentherapie und Onkologie

Volumn 191, Issue 1, 2015, Pages 7-16

  Golcher, Henriette ^a   Brunner, Thomas B ^a,b   Witzigmann, Helmut ^c,d   Marti, Lukas ^e   Bechstein, Wolf Otto ^f   Bruns, Christiane ^g,h   Jungnickel, Henry ^d   Schreiber, Stefan ^c   Grabenbauer, Gerhard G ^a,i   Meyer, Thomas ^a,j   Merkel, Susanne ^a   Fietkau, Rainer ^a   Hohenberger, Werner ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^e Hospital of St Gallen   (Switzerland)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

ⁱ KLINIKUM COBURG   (Germany)

^j Ansbach District Hospital   (Germany)

more..

Author keywords

Adenocarcinoma; Chemoradiation; operative; Pancreas; Surgical procedures; Survival

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ABDOMINAL ABSCESS; ADJUVANT THERAPY; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHOLANGITIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PANCREAS CANCER; PEROPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION INDUCED EMESIS; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; ADJUVANT CHEMORADIOTHERAPY; AGE DISTRIBUTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; EPIDEMIOLOGY; GERMANY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOADJUVANT THERAPY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PREVALENCE; PREVENTION AND CONTROL; PROCEDURES; RISK FACTOR; SEX RATIO; SURVIVAL RATE; SWITZERLAND; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE; SWITZERLAND; TREATMENT OUTCOME;

EID: 84922003057     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0737-7     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29
2. Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030–1047
3. Heald RJ, Moran BJ, Ryall RD et al (1998) Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg 133:894–899
4. Glimelius B, Pahlman L, Cervantes A (2010) Rectal cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5:v82–86
5. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740
6. Rodel C, Liersch T, Hermann RM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:110–117
7. Quirke P, Durdey P, Dixon MF et al (1986) Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 2:996–999
8. Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210
9. Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277
10. Regine WF, Winter KA, Abrams RA et al (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299:1019–1026
11. Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081
12. Adler G, Seufferlein T, Bischoff SC et al (2007) S3-Guidelines “Exocrine pancreatic cancer” 2007. Z Gastroenterol 45:487–523
13. Papalezova KT, Tyler DS, Blazer DG, 3rd et al (2012) Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol 106:111–118
14. Wayne JD, Abdalla EK, Wolff RA et al (2002) Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 7:34–45
15. Snady H, Bruckner H, Cooperman A et al (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89:314–327
16. Evans DB, Varadhachary GR, Crane CH et al (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496–3502
17. Golcher H, Brunner T, Grabenbauer G et al (2008) Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol 34:756–764
18. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267
19. Brunner TB, Grabenbauer GG, Meyer T et al (2007) Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 7:41
20. Lu DS, Reber HA, Krasny RM et al (1997) Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. Am J Roentgenol 168:1439–1443
21. Fokas E, Eccles C, Patel N et al (2013) Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor. Strahlenther Onkol 189:407–416
22. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours. 6th edn. Wiley, New York
23. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
24. National Cancer Institute Common Toxicity Criteria, Version 2.0: Cancer Therapy Evaluation Program. 1998 http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. Accessed 1 Sept 2014
25. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346
26. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
27. Oettle H, Neuhaus P, Hochhaus A et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473–1481
28. Esposito I, Kleeff J, Bergmann F et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660
29. Menon KV, Gomez D, Smith AM et al (2009) Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 11:18–24
30. Zhang Y, Frampton AE, Cohen P et al (2012) Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg 16:1875–1882
31. Brunner TB, Merkel S, Grabenbauer GG et al (2005) Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 62:1021–1029
32. Zhu CP, Shi J, Chen YX et al (2011) Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 99:108–113
33. Crane CH, Wolff RA, Abbruzzese JL et al (2001) Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28:25–33
34. Naumann P, Habermehl D, Welzel T et al (2013) Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Strahlenther Onkol 189:745–752
35. Combs SE, Habermehl D, Kessel K et al (2013) Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort. Strahlenther Onkol 189:738–744
36. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332